Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Johnson & Johnson (NYSE:JNJ) is on the up after a post-earnings plunge earlier this week. The firm marginally beat guidance in the fourth quarter but issued lower-than-expected guidance. Still, it’s retained the confidence of some Street experts.
The Rating
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Raymond James analyst Jayson Bedford maintained an Outperform on the stock but cut his price target from $149 to $145.
Morgan Stanley analyst David Lewis maintained an Equal Weight rating and raised his price target from $130 to $134.
Immediate Prospects
A myopic look at Johnson & Johnson warrants skepticism about its prospects. The company suffers forex headwinds, continued overhang from the talc lawsuit, and biosimilar and generic competition driving revenue growth deceleration.
“However, this is factored into current sentiment,” Bedford assured in a Wednesday note. “We see potential upside to management’s initial 2019 guidance and believe the balance sheet still holds some optionality, which keeps us constructive on the name.”
Organic Growth
Low organic growth projections also discouraged both analysts, although Bedford predicted upside to the pharma and consumer businesses.
“We also note that J&J started 2018 with organic growth guidance of 2.5-3.5 percent and ended up growing ~5.5 percent, organically,” Bedford wrote. “There is a recent track record of under-promising/over-delivering.”
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Lewis also suspects conservative guidance for organic growth and anticipates strength specifically in the consumer and MD&D lines.
“In Consumer, we see our estimate of 3.5 percent as achievable as J&J grew 3.2 percent in 2018 and initiatives including the Baby relaunch and new Beauty and Oral Care products are expected to maintain momentum,” he wrote.
Pharma Declines
Given $1.6 billion in net divestitures and heightened competition in pharma, Bedford reduced his overall and segmented forecasts for organic growth acceleration.
Again, Lewis presumes conservative guidance for pharma — an important metric highly-correlated with the stock price.
“Clearly this is a year with outsized headwinds and less indicative of the company's underlying Pharma fundamentals (Darzalex, Imbruvica, & Stelara) and pipeline (Tremfya and Erleada), but it does raise a question we posed in our Diversity is a Three-Way Street note about how overexposure to Pharma may be weighing on the company's multiple and stock performance,” he wrote.
Price Action
At time of publication, shares traded up marginally at $129.25.
Related Links:
Jury Upholds $4.69B Verdict In Johnson & Johnson Baby Powder Case
Johnson & Johnson CEO Tells Cramer 'Thousands Of Studies' Refute Asbestos Allegations
Photo credit: Raysonho @ Open Grid Scheduler via Wikimedia Commons
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.